Multiple reports in the New England Journal of Medicine describe Phase 3 clinical trial results assessing inhaled treprostinil in people with idiopathic pulmonary fibrosis (IPF). The studies evaluate inhaled treprostinil as a treatment option and report outcomes from the Phase 3 program, focusing on clinically relevant measures of disease progression in this patient population. Across the reports, the emphasis is on the trial design and the prespecified endpoints used to judge whether inhaled treprostinil provides benefit compared with a control approach. The publications present the evidence basis for the efficacy and safety assessment, including how participants are selected, how dosing is administered via inhalation, and how outcomes are monitored over the study period. The NEJM publications also outline the main findings in terms of the trial’s primary and secondary endpoints and summarize safety observations relevant to inhaled treprostinil use in IPF. Overall, the coverage frames the Phase 3 results as a key step in establishing the evidence for inhaled treprostinil in idiopathic pulmonary fibrosis.